07

NANOSYSTEMS: PHYSICS, CHEMISTRY, MATHEMATICS, 2014, 5 (1), P. 67–75

TOWARD PACLITAXEL–[60]FULLERENE IMMUNOCONJUGATES AS A TARGETED PRODRUG AGAINST CANCER

Y. Mackeyev – Department of Chemistry and The Smalley Institute for Nanoscale Science & Technology, Rice University, Houston, TX; mackeyev@rice.edu
M. Raoof – Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX; mustafaraoof@yahoo.com
B. Cisneros – Department of Chemistry and The Smalley Institute for Nanoscale Science & Technology, Rice University, Houston; Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX; brandon.cisneros@gmail.com
N. Koshkina – Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX; nvkoshki@mdanderson.org
C. S. Berger – Department of Chemistry and The Smalley Institute for Nanoscale Science & Technology, Rice University, Houston, TX; csberger@rice.edu
L. J. Wilson – Department of Chemistry and The Smalley Institute for Nanoscale Science & Technology, Rice University, Houston, TX; durango@rice.edu
S. A. Curley – Baylor College of Medicine, One Baylor Plaza, MS390, Houston, TX 77030; steven.curley@bcm.edu

Two newly synthesized water-soluble conjugates of Paclitaxel with malonodiserinolamide-derivatized [60]fullerene (C₆₀-ser) undergo hydrolysis and release their medical payload under biological conditions. In vivo testing of
one of these compounds in a murine model showed tumor volume reduction similar to the FDA-approved drug Abraxane, but without the associated weight-loss, indicating better tolerance of this new formulation.

Keywords: Fullerene, Paclitaxel, Cancer, Immunoconjugate.

PACS 81.20.Ka; 81.05.ub; 87.19.xj; 87.85.Qr, 87.85.Rs

Download